Testing effectiveness (Phase 2)WithdrawnNCT05039736
What this trial is testing
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Who this might be right for
Hepatocellular CarcinomaLiver Cancer
M.D. Anderson Cancer Center